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Abstract: Our aim was to evaluate the intake of foods containing fermentable oligo/di/mono-
saccharides and polyols (FODMAP) as a possible factor that induces gastrointestinal symptoms in
treated celiac disease (CD) patients. We collected seven-day weighed food records for 104 CD patients
and 91 healthy volunteers. All evaluated food items were from sources with high and low content of
FODMAP, which were divided into cereals and sweets, sweeteners and soft drinks, fruits, dried fruits,
and vegetables. Nutrient intake was calculated using the food database of the European Institute
of Oncology. The symptoms reported were assessed by a Rome IV Irritable bowel syndrome (IBS)
diagnostic questionnaire and by specific questions for the evaluation of functional gastrointestinal
disorders (FGIDs). The 12% of CD patients met IBS symptoms criteria as opposed to 6% of controls
(p = 0.09) and 27% of patients reported FGIDs symptoms vs. 22% of healthy controls (p = 0.42).
The intake by CD patients was significantly higher than healthy volunteers for: sweeteners and
sugars with low content of FODMAP (p = 0.0007), fruits, dried fruits, and vegetables high in FODMAP
(p = 0.003) and low in FODMAP (p = 0.04) when compared to controls. CD patients had a lower intake
of cereals and sweets with a high content of FODMAP (p = 0.00001). Healthy volunteers consumed
significantly higher alcoholic beverages and fats high in FODMAP (both p < 0.044). The mean daily
intake of other food categories did not differ between both groups. Even though CD patients had
a low intake of gluten-free cereals high in FODMAP, they still consumed a significant amount of
fruits and vegetables high in FODMAP. The clinical effect of a concomitant gluten-free diet and
low-FODMAP diet should be prospectively evaluated as a supportive therapy in CD patients.
Keywords: FODMAP intake; celiac disease; irritable bowel syndrome; gluten-free diet; gastrointestinal
symptoms
1. Introduction
Celiac disease (CD) is a chronic autoimmune enteropathy triggered by dietary exposure to gluten
and is characterized by villous atrophy. CD is considered the most common chronic enteropathy
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in Western countries with an estimated prevalence ranging from 0.5 to 1% [1,2]. An altered T cell
mediated immune response triggered by gluten has a central role in the pathogenesis of CD. Genetic
predisposition plays a key role in the development of CD and the presence of the HLA DQ2 and/or DQ8
haplotypes is a necessary (but not sufficient) factor [3,4]. CD patients may present with gastrointestinal
symptoms, extra-intestinal symptoms, or no symptoms at all. The classical clinical symptoms include
diarrhea, steatorrhea, and weight loss due to malabsorption [5].
Gluten is a complex of high molecular-weight proteins found in the endosperm of grass-borne
grains including wheat, barley, and rye [6]. The treatment of CD is the withdrawal of gluten from
the diet (i.e., a gluten-free diet, GFD), which usually silences symptoms and normalizes serological
and histological signatures. CD is considered a lifelong disorder and, if left untreated, is associated
with increased morbidity and mortality [7,8]. Despite the strict adherence to a GFD, there is a group
of CD patients who keep suffering from functional gastrointestinal disorders (FGIDs) [9]. FGIDs
include irritable bowel syndrome (IBS) and non-specific gastrointestinal symptoms (pain, diarrhea,
bloating, nausea, vomiting). IBS is currently identified to be a global problem with a prevalence of
11%, which specifically affects women as compared to men (14.0% vs. 8.9%, respectively) [10,11].
IBS is characterized by a multiplicity of clinical symptoms such as abdominal pain, bloating,
and changes in bowel habits including constipation and/or diarrhea. It also compromises the patients’
abilities and quality of life, which implicates an increase in healthcare provision costs, use of drugs,
and absence/leave from work [12].
The criteria for diagnosing gastrointestinal disorders have been revised by the Rome Foundation
in their latest update (Rome IV, 2016). The pathogenesis of IBS is multi-factorial and may be
connected to visceral hyper-sensitivity, alterations of the gut-brain axis and the microbiota, post
infectious consequences, and environmental and genetic factors [13]. IBS can be suspected in patients
suffering from persistent abdominal pain associated with more than one condition: defecation,
change in the frequency of defecation, and change of stool form [14]. Moreover, IBS can be
classified as IBS-C (predominant constipation), IBS-D (predominant diarrhea), and IBS-M (mixed) [15].
Nowadays medication (antispasmodics, bulking agents, probiotics, laxatives, or anti-depressants), diet,
and lifestyle adjustments have been the main therapeutic options for IBS [16].
In recent years, data supporting that the dietary restriction of fermentable oligo/di/mono-
saccharides and polyols (FODMAP) for the management of IBS symptoms have emerged [17–19].
Studies evaluating a low-FODMAP diet in patients with IBS have consistently shown symptomatic
benefits in the majority of patients [20]. However, one study that compared the diet commonly used
in these patients vs. a low-FODMAP diet failed to demonstrate differences in the improvement of
the symptomatology [21]. The use of the low-FODMAP diet has been evaluated in other digestive
pathologies with contradictory results. Pedersen et al. showed some degree of improvement in
functional gut symptoms of patients with inflammatory bowel disease (IBD) [22] while Cox et al.
showed exacerbated functional gastrointestinal symptoms in patients with IBD [23]. On the other
hand, Testa et al. were able to demonstrate that a low-FODMAP diet could be one option to counteract
abdominal symptoms in patients with IBS, non-active IBD, or CD on a GFD, which improves their
quality of life [24].
The main dietary sources of FODMAP include fructose in honey, apples, and pears, fructans in
wheat, rye, onion, and garlic, galactans in cabbage and legumes, lactose in milk and dairy products,
and polyols including sorbitol and mannitol in stone fruits, mushrooms, and artificial sweeteners [25].
Among FODMAP, fructans and galacto-oligosaccharides are considered prebiotics. Prebiotics are
non-digestible selectively fermented dietary fibers that promote the growth of positive bacterial genera
in the gastrointestinal tract. Prebiotics such as inulin-type provides health benefits to the host [26].
These non-digestible food ingredients are also extensively employed in the food industry [27]. The main
feature of these carbohydrates is their poor absorption in the small bowel. This is due to different
reasons including reduced or absent digestive enzymes or by their slow transport across the intestinal
mucosa. Undigested and unabsorbed FODMAP have the peculiarity to be highly osmotic and rapidly
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fermented by bacteria in the gut, which causes distension, bloating, cramping, and diarrhea, which are
all symptoms found in IBS [28]. Moreover, high concentrations of FODMAP in the ileum and proximal
colon exert osmotic pressure, which draws greater amounts of water into the lumen [29]. Fermentation
as produced by short-chain FODMAP intensifies the luminal H2 and CH4 production and causes pain
in the lumen. This gas production can be measured with a breath test, which shows an increase between
0–5 h after the ingestion of FODMAP [30]. As proposed mechanisms, it has been recently shown as
a link between FODMAP and inflammation induction in vivo [31]. Zhou et al. [32] reported that a
high-FODMAP diet could increase the serum lipopolysaccharide level and intestinal inflammation
together with visceral hypersensitivity. On the contrary, a diet low in FODMAP could reduce LPS
levels and the inflammatory status.
Nowadays, it is of great interest to evaluate if persistent gastrointestinal symptoms in celiac
patients, classified as FGIDs and IBS, can be provoked by the ingestion of FODMAP. We aimed to
evaluate the intake of foods containing FODMAP in a group of patients with CD compared with the
intake of healthy volunteers.
2. Materials and Methods
2.1. Patients
The participants were recruited among patients referred to the Center of Prevention and Diagnosis
of Celiac Disease Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. All the
subjects were recruited between October 2012 and August 2014 and the data were collected during the
same period. Over that time, during their annual medical examination, the patients were screened for
their adherence to GFD by using the celiac diet adherence test (CDAT) [33].
The enrolment process of CD patients and healthy individuals has been previously
described [34,35]. All patients included in the study fulfilled the Rome IV questionnaire criteria
for IBS, functional dyspepsia, and functional bloating [15]. In detail, each patient was asked if they
have had recurrent abdominal pain arising for at least 6 months and being present at least once a
week in the last 3 months, which is associated with changes in the stool’s volume and consistency.
The presence of diarrhea and/or constipation associated with abdominal pain was confirmed in case
of presence of IBS. They were also asked for the presence of dyspepsia and/or any other functional
symptoms such as bloating (for FGIDs). The exclusion criteria were: CD diagnosis less than two years,
the presence of metabolic or chronic disease (e.g., diabetes mellitus, Crohn’s Disease, cardiovascular
and neuro-vascular disease, cancer, neuro-degenerative disease, and rheumatoid arthritis), pregnancy
or lactation, vegetarianism, or veganism. A group of healthy volunteers was recruited among students,
researchers, and professors of the Universities of Parma, Parma, and University of the Studies, Milan.
For healthy volunteers, CD was excluded by means of serological tests (anti-tissue transglutaminase
IgA). Exclusion criteria for the healthy participants were the same as for the CD patients except for the
diagnosis of CD.
The final sample included 104 celiac patients and 91 healthy controls. All the participants who
agreed to participate signed a written informed consent and were enrolled in the study. The local
Ethics Committee for Human Research of the City of Milan approved the protocol. The study was
registered at ClinicalTrials.gov (ID NCT01975155).
2.2. Dietary Records
The total food and beverage consumption was assessed by using a food diary filled in daily
for a total of seven days, which was previously described [36]. The participants were trained on
how to record all of the food consumed by a nutritionist. The participants were asked to send their
completed seven-day weighed food record to the Department of Food and Drugs of the University of
Parma. A nutritionist reviewed the diaries and, in case of any error or omission, the participants were
contacted by phone to clarify the issues.
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The nutrient intake was calculated by using a Microsoft Access application (version 2003,
Microsoft Corp, Redmond, WA, USA) linked to the European Institute of Oncology’s food database,
which covered the nutrient composition of 900+ Italian foods [37], integrated with the nutrient
composition of 60 gluten-free foods available in the Italian market [38]. When a food recorded
in a participant’s seven-day weighed food record could not be found in the database, an alternative
food was appropriately chosen based on similarities in energy and nutrient composition. The output
consisted of the mean daily intake of energy and food items for each individual.
Food items of interest for the FODMAP intake evaluation were grouped into the following food
categories (a summary of food sources of FODMAP, as reported in the literature, is provided in Table 1):
pasta, bread (including crackers and salty snacks), other cereals (including corn, quinoa, buckwheat,
and rice), fruits, vegetables and legumes, sweeteners (honey, saccharin, fructose, barley malt syrup),
and sweets (including biscuits, sweet snacks, breakfast cereals, ice cream, candies, and chocolate),
dried fruits, oil and fats, dairy products (including milk, yogurt, cream, cheese), soft drinks, juices,
coffee/tea, and alcoholic beverages [18]. The categories of foods high and low in FODMAP content
were also grouped in larger or macro-categories: cereals and sweets, sweeteners and soft drinks, fruits,
dried fruits, and vegetables. For each individual, the mean daily intake of each food macro-category,
i.e., low and high-FODMAP contents, was calculated.
Table 1. Foods with high and low amounts of FODMAP †.
Food Category High in FODMAP Low in FODMAP
Alcoholic beverages Sweet wine, rum, vodka, whiskey Beer, red wine, rosè wine, white wine,sparkling wine, gin
Cereals Wheat, barley, rye, bran, whole wheatflour, spelt, Kamut® (Khorasan wheat)
Quinoa, rice, buckwheat, pearl millet, corn,
gluten-free flour, bulgur, sourdough spelt bread,
cornflakes, puffed rice
Sweets Apricot jam, peach jam, blackberry jam,plum jam, milk chocolate
Strawberry jam, peanut butter, lactose-free ice
cream, gluten-free sweets
Sweeteners Honey, saccharin, fructose, malt syrup Aspartame, sucrose, sugar, brown sugar
Fruit
Apple, apricot, avocado, ripe banana,
blackberry, litchi, mango, white peach,
yellow peach, pear, persimmon,
pomegranate, blackcurrant, cranberry,
plum, watermelon, cherry
Banana, blueberry, strawberry, raspberry, melon,
white melon, kiwi, orange, mandarin orange, red
grapes, black grapes, green grapes, lemon,
coconut, pineapple, loquat, papaya, prickly pear,
passion fruit, grapefruit
Dried fruit Raisin, dried date, apple, apricot, fig,mango, pear, plum, cashew nut, pistachio
Hazelnut, pine nut, walnut, flax seed, sunflower
seed, dried banana, coconut, dried cranberry,
dried coconut
Fats Butter, margarine, cream, lard
Olive oil, extra-virgin olive oil, sunflower oil,
almond oil, peanut oil, linseed oil, sesame oil, rice
oil, palm oil, coconut oil, colza oil, soybean oil
Dairy products Milk, yogurt, fresh cheese, semi-agedcheese, aged cheese
Lactose-free milk, lactose-free yogurt, lactose-free
cheese, feta, cottage cheese, Parmesan
Soft drinks Apple juice, orange juice, apricot juice,pear juice, peach juice, pomegranate juice
Pineapple juice, lemon juice, cranberry juice,
vegetables juice, orange fresh-squeezed juice
Vegetables
Red radicchio, green radicchio, artichoke,
asparagus, cauliflower, red cabbage, green
cabbage, sauerkraut, pea, snow pea,
mushroom, garlic, leek, onion, Jerusalem
artichoke, bean, white bean, lupine bean,
broad bean (Vicia fabai), chickpea,
broccoli, beet
Pepper, carrot, eggplant, zucchini, potato, sweet
potato, tomato, lettuce, fennel, fennel leaves,
spinach, chard, radish, green bean, turnip,
chicory, rocket, stick, watercress, endive, valerian,
olive, sweet corn, chestnut, pumpkin flower,
cucumber, chives, chili pepper, ginger, Brussels
cabbage, soy sprout, bean sprout, healing herb,
okra, truffle, green alga, celery, pumpkin
† Examples of foods classified as having the high and low amount of FODMAP. FODMAP: fermentable
oligo/di/mono-saccharides and polyols.
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2.3. Statistical Analysis
Data were accordingly described as mean ± SD or median (with interquartile range), according
to variables’ distribution (evaluated by the Shapiro-Wilk test). The Pearson chi-square test was used
to compare the number of individuals reporting IBS and FGIDs in between both studied groups.
The daily nutrient intake data of energy, water, and FODMAP-containing foods were computed and
tabulated. To reduce the effect of implausible extreme values on the analysis, we checked that the
ratio of total energy intake determined from the food record to the basal metabolic rate (determined
by the Harris-Benedict equation) of each participant was not in the first or the last percentile of the
distribution. The dietary data were compared between the control patients and the celiac disease
patients by using the independent sample Student’s t-test or the Wilcoxon rank-sum test. STATA® v.
13.1 (StataCorp, College Station, TX, USA) was used in all the analyses. Statistical significance was set
at a 5% α-level.
3. Results
Patients
Patients in the CD group were older (p = 0.0002) and there was a higher percentage of females in
both groups (82.7% and 68.1% of CD patients and controls, respectively). Both groups were comparable
regarding their mean BMI (22.4 ± 3.3 and 22.2 ± 3.0 for the CD and control group, respectively) and
daily energy intake (2054.8 kcal (397.3) and 2044.7 kcal (329.3)), respectively. When analyzing the
prevalence of gastrointestinal symptoms in both groups, we found out that 12% of CD patients suffered
from IBS when compared with 6% of the controls (p = 0.09) while 27% of CD patients suffered from
FGIDs symptoms (5.77% functional dyspepsia, 10.58% functional bloating) against 22% of controls
(p = 0.42). Approximately 10.5% of CD patients did not suffer from either IBS, functional dyspepsia,
or functional bloating (Figure 1).
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Table 2. Daily dietary intake of celiac patients and healthy controls.
Dietary Intake Healthy Controls(n = 91)
Celiac Patients
(n = 104) p Value
†
Food intake, g/day 1569.5 ± 337.0 1656.5 ± 284.2 0.05 ‡
Energy intake, kcal/day 2054.8 (397.3) 2044.7 (329.3) 0.68
Water intake, mL/day 742.8 (400.0) 647.1 (452.6) 0.52
High-FODMAP, g/day 681.4 (261.0) 457.4 (208.4) 0.00001
Low-FODMAP, g/day 835.1 (364.8) 1119.6 (366.9) 0.00001
High-FODMAP, % 45 (10) 28 (10) 0.00001
Low-FODMAP, % 54 (10) 71 (10) 0.00001
Data as median values (IQR) unless otherwise is indicated. a data as mean ± SD. † p value for the Wilcoxon
rank-sum test unless otherwise is indicated. ‡ p value for the t-test for two independent groups.
The analysis of FODMAP-containing food intake according to food categories is shown in Tables 3
and 4. The consumption of high-FODMAP foods was higher in the control group with the exception
of fruits, which was higher in the CD group. In turn, low-FODMAP food consumption was greater
in the CD group. A larger amount of high-FODMAP cereals (p = 0.0001), high-FODMAP sweets
(p = 0.0001), high-FODMAP alcoholic beverages (p = 0.0001), and high-FODMAP fats (p = 0.0447) was
observed in the control group when compared to celiac patients. Instead, the CD group consumed
significantly higher amount of cereals with low FODMAP content (p = 0.0001), low-FODMAP sweets
(p = 0.0001), low-FODMAP sweeteners (p = 0.0099), fruit both high and low in FODMAPs (respectively
p = 0.001 and p = 0.0158), and low-FODMAP juices (p = 0.0228). The mean daily intake of the other
food categories did not differ between the two groups (Table 3).
Table 3. Daily intake of food categories containing low and high amounts of FODMAP by celiac
patients and healthy controls.
Food Categories (g/day)
Healthy Controls Celiac Patients








Alcoholic beverages, g/day 5.7 (57.1) 21.4 (64.2) 0 (5.7) 6.7 (61.1) 0.0001 0.22
Cereals, g/day 228.0 (61.1) 171 (30.7) 0 (0) 222.7 (95.1) 0.0001 0.0001
Sweets, g/day 22.8 (32.1) 2.1 (11.4) 2.8 (9.1) 35.7 (51.6) 0.0001 0.0001
Sweeteners, g/day 0 (1.6) 6.4 (8.8) 0 (1.2) 8.2 (11.7) 0.49 0.0099
Fruits, g/day 45.7 (108.7) 85.7 (115.7) 100.4 (126.8) 116.4 (128.0) 0.001 0.0158
Dried fruits, g/day 0 (0.2) 0 (2.1) 0 (0) 0.5 (4.1) 0.53 0.28
Fats, g/day 3.3 (6.7) 25.7 (14.4) 2.4 (5.6) 26.0 (13.6) 0.0447 0.25
Dairy, g/day 188.6 (211.4) 7.4 (16.4) 196.2 (184.2) 7.5 (17.6) 0.61 0.85
Juices, g/day 1.4 (47.1) 0 (2.8) 25.7 (67.8) 0.7 (34.2) 0.49 0.0228
Vegetables, g/day 55.0 (87.4) 236.2 (146.4) 73.1 (85.8) 245.8 (139.6) 0.21 0.60
Data as median values (IQR). * p value for comparisons between groups regarding high-FODMAP foods. ** p value
for comparisons between groups regarding low-FODMAP foods.
When the foods containing FODMAP were grouped into large categories (i.e., cereals and sweets,
sweeteners and sugars, fruits, dried fruits, and vegetables), a higher consumption of cereals and sweets
with high FODMAP content was present in the control group (p = 0.00001) while CD patients showed
significantly higher consumption of fruits, dried fruits, and vegetables with high FODMAP content
(p = 0.003). In addition, other large categories of foods with low FODMAP content were significantly
more consumed by the CD patients as compared to the control group (Table 4). Lastly, no correlation
between FODMAP intake and gastrointestinal symptoms was found.
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Table 4. Daily intake of grouped food categories containing low and high amounts of FODMAP by
celiac patients and healthy controls.
Food Categories
Healthy Controls (n = 91) Celiac Patients (n = 104)








Cereals & sweets, g/day 253.7 (74.2) 28.6 (37.4) 3.6 (11.4) 265.8 (103.4) 0.00001 0.00001
Sweeteners & sugar, g/day 14.2 (47.1) 9.0 (14.4) 28.6 (73.6) 15.4 (38.5) 0.64 0.0007
Fruits, dried fruits &
vegetables, g/day 135.0 (185.2) 360.7 (175.2) 181.3 (126.0) 399.8 (232.1) 0.003 0.04
Data as median values (IQR). * p value for comparisons between groups regarding high-FODMAP foods. ** p value
for comparisons between groups regarding low-FODMAP foods.
4. Discussion
This is the first time that a classification is made in relation to food consumption, according to
the amount of FODMAP in patients with CD. In our study, 12% of CD patients met the Rome IV
symptom criteria and 27% suffered from FGIDs symptoms. The data available confirms that the
prevalence of IBS-type symptoms among the group of celiac patients is higher than that in a group of
control subjects [39]. While it was true, CD patients showed a low intake of high FODMAP cereals,
which reflects treatment with a GFD. We observed that the intake of high FODMAP fruits in this group
could in some way be associated with the higher percentage of CD patients reporting IBS and FGIDs
symptoms as compared to controls [40].
When CD is diagnosed, there is usually the assumption that gastrointestinal symptoms will
resolve once gluten is eliminated from the diet. Instead, it has been demonstrated that some celiac
patients carry on suffering of gastrointestinal symptoms one year after diagnosis even with their
correct adherence to GFD and normalization of serum tTG levels [9]. Such a finding also includes the
fact that celiac patients do not report great quality-of-life scores as compared to those of the healthy
population [41]. Therefore, the hypothesis that only mucosal inflammation may have a sensitizing
effect or predispose to IBS-type symptoms is not the only way to run. The diet can play a pivotal role in
the induction of IBS symptoms [42] especially FODMAP [43]. IBS is a common syndrome characterized
by abdominal discomfort or pain and is associated with altered bowel habits [14]. Currently, once
major organic gastrointestinal disorders have been excluded, specialists focus on the possible link
between an “IBS” clinical picture and molecules such as α-amylase/trypsin inhibitors (resistance
molecules contained in cereals to fend off pests and parasites) or dietary habits such as the intake of
lactose, dietary nickel, poorly absorbed, and short-chain carbohydrates (i.e., FODMAP). FODMAP are
contained in different types of cereals such as wheat, barley, rye, and derived products and sweets
and sweeteners such as honey, saccharin, and fructose. There are two other categories that contain
high levels of FODMAP including several types of fruits/dried fruit (such as apple, apricot, peach,
pear, watermelon, and plum) and vegetables (such as artichoke, asparagus, cauliflower, onion, garlic,
and beans). In addition, dairy products are given attention for their high FODMAP content (lactose):
milk, yogurt, fresh cheese, semi-aged cheese, and aged cheese. At present, no data is available about
FODMAP intake in CD patients [44,45].
In our study, a group of celiac patients was compared with a group of healthy subjects with
regard to their intake of FODMAP through foods containing different (low and high) levels of them.
We recorded all the foods and beverages consumed during a week and then consumed foods that
were classified as being high or low in FODMAP content. We used such an approach since the
direct measurement of FODMAP content by means of reliable analytical methods in common foods is
unavailable yet. As expected, CD patients had a lower intake of cereals and sweets containing high
FODMAP levels (including the gluten-containing grains forbidden to celiac patients) as compared to
healthy volunteers. Conversely, patients had a higher intake of low FODMAP cereals including cereals
allowed in GFD such as rice, corn, and pseudo cereals. Interestingly, a significantly higher intake of
fruits (both high and low in FODMAP) was found in the CD patients. Moreover, when all vegetable
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foods, i.e., fruits, dried fruits, and vegetables were grouped together, we observed a significantly
high intake of both categories in CD patients when compared to healthy volunteers. This suggests
a greater level of attention about a healthy diet paid by CD patients than controls. However, since
cereals contain fructans, fruit and vegetables are two food categories with a high content of FODMAP.
This high intake of fruits rich in FODMAP might partly explain the tendency to a higher number
of CD patients reporting IBS and FGIDs symptoms when compared to controls. When comparing
sweeteners intake, both groups had a comparable low intake of high-FODMAP foods. This suggests
that fructose as a sweetener was not commonly used by all the volunteers. In fact, only 12 out of
91 controls and 11 out of 104 CD patients made use of it (data not shown). By contrast, CD patients
consumed more low-FODMAP sweeteners such as sugar and aspartame than controls. Lastly, the
results suggest that patients with CD did not exclude or limit dairy products with a high content of
FODMAP, which shows a pattern similar to that of the control group. Of note, milk and its derivatives
provide important nutrients due to its content of vitamins, minerals, and macronutrients essential for
the growth, development, and maintenance of tissues [46]. On the other hand, the benefits of the fatty
component of dairy products have been demonstrated and elicit a greater bioavailability of high-value
nutrients and also show anti-inflammatory properties [47–49]. The presumed anti-inflammatory
benefits described in dairy products could potentially be the reason, at least in part, why some CD
patients can tolerate them despite the secondary lactose intolerance described in some of them.
Currently, little is known about the level of FODMAP intake in different population groups.
Nevertheless, it is of great interest to confirm a potential relationship between specific dietary
carbohydrates and gastrointestinal symptoms [25]. FODMAP have been reported as triggers of
gastrointestinal symptoms in IBS, Crohn’s disease, and ulcerative colitis with the hypothesis being that
the rapid fermentation and passage of FODMAP through the gastrointestinal tract leads to an increase
in intestinal permeability [50]. Particularly in IBD patients who have superimposed IBS, the luminal
distension (caused by the fermentation of FODMAP by bacteria in the distal small and proximal large
bowel) can cause gastrointestinal symptoms such as bloating, distension, cramping, and diarrhea [51].
There are few antecedents on the long-term effectiveness, acceptability, and nutrient adequacy of a
diet with low FODMAP content. Studies have evaluated retrospectively and prospectively changes in
the gastrointestinal symptomatology [52–54] while long-term nutritional characteristics of a diet with
low FODMAP content had not been studied. O’Keeffe et al. [55] evaluated the long-term impact of
the low FODMAP diet on clinical response, nutritional adequacy, dietary acceptability, and quality of
life related to foods. The authors concluded that the education provided in relation to a diet with low
FODMAP content is effective in the management of IBS by allowing the maintenance of a nutritionally
adequate diet among patients. However, one unintended consequence associated with FODMAP
restriction is its impact on the gut microbiota. Probiotic supplementation with Bifidobacterium is
associated with a reduction in IBS symptoms but the low FODMAP diet markedly reduces luminal
Bifidobacterium concentration [56]. It is likely that both interventions can be successful in specific
groups of patients [30]. In this sense, Staudacher et al. [19] showed that a low-FODMAP diet was
associated with adequate relief of symptoms in patients with IBS when compared to the placebo and
concomitant administration with probiotics (Bifidobacterium) could be administered to restore these
bacteria in patients on a low-FODMAP diet.
For the first time, this study evaluated the intake of low or high-FODMAP foods in CD patients
affected by IBS and FGIDs symptoms. As limitations, we would like to mention that our results
were obtained through food diaries in a seven-day period, which is a period of time that is short
and does not allow conclusions about the long-term impact of this dietary pattern. Even though the
recording period is short, the participants accurately reported and weighed all the consumed food
and beverages. Moreover, in a previous publication on almost the same participants, we compared
this tool to a food frequency questionnaire and demonstrated that the two tools were correlated
especially in terms of food groups [34]. The study of the diet during a longer period of time could
provide relevant knowledge regarding dietary characteristics in patients with CD. Because of the
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explorative nature of our study, we could not find any causative relationship between the intake
of FODMAP-rich foods and the presence of gastrointestinal symptoms in our patients. However,
the clinical effect of a GFD together with low-FODMAP diet should be prospectively evaluated as
a supportive therapy for CD patients. In this sense, our group has recently reported that a GFD
associated with a low-FODMAP content is beneficial as a supportive therapy for a group of CD
patients with persistent gastrointestinal symptoms [57]. When consolidated data on the FODMAP
content of foods become available, it will allow the investigation of specific FODMAP groups among
oligosaccharides, disaccharides, monosaccharides, and polyols that are more consumed by CD patients
than by controls.
ClinicalTrials.gov, ref. no. NCT01975155.
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